Become an Industry Collaborator
Industry Collaboration Team
The ICT program was originally designed to develop, foster and facilitate a two-way communication channel between our pharmaceutical partners and the GOG Foundation, Inc. physician leadership. This was managed by setting up the opportunity to meet twice yearly at the NRG Semi-Annual Meetings for approximately (40) minutes.
As time progressed, the GOG further recognized the need for additional meetings to collaborate with our industry partners outside of formal clinical operations calls or advisory boards. The ICT program has since expanded to include more opportunities throughout the year in a formal setting. These opportunities allow our industry colleagues to focus on strategy, and engagement, while our team focuses on assuring that the right leaders are engaged to facilitate the important discussions needed. The GOG Foundation strives to build a strong partnership with Industry to serve as their research and collaborative partner, thus facilitating advancement in the field of gynecologic oncology.
This yearly membership opportunity as an ICT Platinum Member* provides:
- The opportunity to establish a two-way communication channel between Industry Partners and GOG that builds opportunities to communicate information about new and improving technologies, equipment, products, and services within gynecologic cancer research.
- Regular Business Strategy Meetings with GOG Leadership (up to four, (50) Fifty-minute meetings) throughout the year at major meetings (SGO Winter, SGO Annual, ASCO, WAGO, ESMO, ESGO, IGCS and (2) NRG/GOG Semi-Annual Meetings.)
- Coordination of face-to-face meetings or virtual meetings handled by GOG Staff, including the invitation process.
- A 60-minute face-to-face reception (2) times per year at the NRG/GOG Semi-Annual Meetings.
- Reduced meeting registration fees at the NRG Semi-Annual Meetings.
- Complimentary advertisement with link to website/webpage in GOG Foundation quarterly newsletter.
- Two (2) social media posts with advertisements on all of GOG Social Networks (Instagram, Facebook, Twitter, LinkedIn).
- Recognition on GOG’s website www.gog.org with company profile, logo, and direct link on website.
- Discounts on Advisory Board meetings, to not include physician FMV honoraria rate.
*Gold membership opportunities may not include all the items noted above. Please see ICT Description of Details for more information
To apply for ICT Membership, please click here to complete the application.
Member Benefits | Platinum $50,000 | Gold $25,000 |
50 Minute Business Strategy Meetings with GOG Leadership:
|
Yes • Up to Four (4) Meetings Per year. |
Yes • Up to Two (2) Meetings Per year. |
Advisory Board Discounts
|
Yes • Platinum members will receive a 5% discount to host an advisory Board meeting at any of the following meetings: ASCO, ESMO, SGO, NRG, IGCS. |
No • Gold Level members can request an upgraded membership for an Ad Board |
Workshops
|
Yes • First five (5) to register are complimentary |
Yes • First two (2) to register are complimentary |
Symposium
|
Yes • First five (5) to register are complimentary |
No • No complimentary registrations |
Company Profile
|
Yes | Yes |
Company Logo
|
Yes |
No
|
Company Website
|
Yes | Yes |
Company Recognition
|
Yes
|
Yes
|
Reception & Dinner To Include ICT Members
|
Yes
|
Yes
|
Aadi Bioscience
Company WebsiteAstraZeneca
Company WebsiteBioNTech
Company WebsiteEisai
Company WebsiteEisai Inc. is a fully integrated pharmaceutical business with discovery, clinical, manufacturing and marketing capabilities. Our key areas of focus include oncology and neurology (dementia-related diseases and neurodegenerative diseases).
Exelixis
Company WebsiteGENENTECH
Company WebsiteGenentech is a leading biotechnology company that discovers, develops, manufactures and commercializes biotherapeutics for significant unmet medical needs. Genentech manufactures and commercializes several major oncology drugs include Herceptin, Rituxan, Avastin and Tarceva.
Genmab
Company WebsiteGenmab is an international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.
GILEAD
Company WebsiteGilead and Kite Oncology are creating the future of oncology. Making bold strides against cancer requires a strategy built on the power of partnerships, groundbreaking technologies and unexpected clinical combinations. We have purposefully built our pipeline with a focus on depth and breadth to address the greatest unmet needs. From antibody-drug conjugates and small molecules to cell therapy-based approaches, our research and development programs are creating possibilities for people with overlooked, underserved, and difficult-to-treat cancers. We are focused on helping to bring more life to people with cancer and changing the way cancer is treated.
ImmunoGen, Inc.
Company WebsiteImmunoGen, Inc. develops targeted anticancer therapeutics. The Company’s ADC technology uses a tumor-targeting engineered antibody to deliver one of ImmunoGen’s highly potent cancer-cell killing agents specifically to tumor cells; the Company has also developed antibodies with anticancer activity of their own. The most advanced compound with ImmunoGen’s ADC technology is Roche’s Kadcyla®. Additional compounds are in clinical testing by ImmunoGen and through the Company’s partnerships with Amgen, Bayer HealthCare, Biotest and Sanofi. More information about ImmunoGen can be found at www.immunogen.com.
Karyopharm Therapeutics
Company WebsitePfizer Oncology
Company WebsiteOur Purpose: We’re in relentless pursuit of breakthroughs that change patients’ lives. We innovate every day to make the world a healthier place. It was Charles Pfizer’s vision at the beginning and it holds true today.